Online citations, reference lists, and bibliographies.
← Back to Search

Safety Of Botulinum Toxin Type A Among Children With Spasticity Secondary To Cerebral Palsy: A Systematic Review Of Randomized Clinical Trials

C. Albavera-Hernández, J. Rodríguez, A. J. Idrovo
Published 2009 · Medicine

Save to my Library
Download PDF
Analyze on Scholarcy
Share
Objective: To assess the safety of botulinum toxin type A for children with cerebral palsy using data from randomized clinical trials. Data sources: A search was conducted of MEDLINE database for the period January 1990 to February 2008. A complementary search was carried out of references from previous reviews. From 122 articles, 20 randomized clinical trials were selected for the review. Review methods: Two authors independently assessed eligibility of the studies and methodological quality of those according to CONSORT guidelines. For each adverse effect, relative risk was calculated, and when more than one study reported adverse effects, a meta-analysis was carried out. Sensitivity analyses with different continuity corrections factors were performed when zero cases were reported in a study arm. Results: There were 882 participants in the 20 studies included in the meta-analysis. Six studies reported zero adverse effects. Thirty-five different adverse events were reported. Botulinum toxin type A use was related to respiratory tract infection, bronchitis, pharyngytis, asthma, muscle weakness, urinary incontinence, falls, seizures, fever and unspecified pain. Two deaths were reported in the study with higher person-time follow-up (relative risk (RR) 4.69, 95% confidence interval (CI) 0.23—95). Conclusions: Botulinum toxin type A has a good safety profile during the first months of use. However the occurrence of adverse events is more frequent among children with cerebral palsy than individuals with other conditions. Severe adverse events are potentially related with the use of botulinum toxin type A, but data are sparse and additional study is required to clarify the causal relation.
This paper references
Botulinum toxin type A for the treatment of spasticity in children with cerebral palsy [Article in Serbian
L Dimitrijević (2007)
10.2307/2347503
Clinical Epidemiology: The Architecture of Clinical Research
K. Macrae (1988)
10.1017/S0012162201002997
Functional outcome of botulinum toxin A injections to the lower limbs in cerebral palsy
D. Reddihough (2002)
10.1007/978-3-319-50592-3
[Cerebral palsy].
P. Grimaud (1972)
10.1542/PEDS.108.5.1062
Botulinum toxin type a neuromuscular blockade in the treatment of equinus foot deformity in cerebral palsy: a multicenter, open-label clinical trial.
L. Koman (2001)
10.1016/J.APMR.2006.10.017
Functional outcomes of intramuscular botulinum toxin type a and occupational therapy in the upper limbs of children with cerebral palsy: a randomized controlled trial.
M. Wallen (2007)
10.1111/j.1469-8749.2000.tb00056.x
Analgesic effects of botulinum toxin A: a randomized, placebo‐controlled clinical trial
S. Barwood (2000)
10.1542/peds.2006-2425
Upper-Limb Botulinum Toxin A Injection and Occupational Therapy in Children With Hemiplegic Cerebral Palsy Identified From a Population Register: A Single-Blind, Randomized, Controlled Trial
R. Russo (2007)
10.1007/S11019-006-9021-7
An agenda for future debate on concepts of health and disease
G. Khushf (2007)
Management of cerebral palsy with botulinum toxin A: Report of a preliminary randomised, double blind trial
LA Koman (1994)
Safety of botulinum toxin type A among children with spasticity secondary to cerebral palsy : a systematic review of randomized clinical trials
C Albavera-Hernández (2009)
The use of botulinum toxin in the treatment of spastic hip joint instability in children with cerebral palsy [Article in Polish
M Jóźwiak (2007)
10.1097/01241398-199405000-00005
Management of spasticity in cerebral palsy with botulinum-A toxin: report of a preliminary, randomized, double-blind trial.
L. Koman (1994)
10.1016/J.PEDIATRNEUROL.2006.09.010
Effect of multilevel botulinum toxin a and comprehensive rehabilitation on gait in cerebral palsy.
V. Scholtes (2007)
10.1002/(SICI)1097-0258(19991030)18:20<2693::AID-SIM235>3.0.CO;2-V
Explaining heterogeneity in meta-analysis: a comparison of methods.
S. Thompson (1999)
10.1067/MPD.2000.108393
An evaluation of botulinum-A toxin injections to improve upper extremity function in children with hemiplegic cerebral palsy.
D. Fehlings (2000)
10.1212/01.wnl.0000316801.74683.c0
Two-year placebo-controlled trial of botulinum toxin A for leg spasticity in cerebral palsy
A. P. Moore (2008)
10.1111/j.1469-8749.2005.tb01173.x
Botulinum toxin A and upper limb functional skills in hemiparetic cerebral palsy: a randomized trial in children receiving intensive therapy
L. Speth (2005)
10.1111/j.1469-8749.2005.tb01215.x
Comparing botulinum toxin A with casting for treatment of dynamic equinus in children with cerebral palsy
J. Ackman (2005)
10.1136/bmj.329.7456.44
Detection, verification, and quantification of adverse drug reactions
B. Stricker (2004)
10.1111/j.1440-1754.2007.01122.x
Botulinum neurotoxin A: An unusual systemic effect
K. Howell (2007)
10.1016/0197-2456(86)90046-2
Meta-analysis in clinical trials.
R. Dersimonian (1986)
10.1016/J.JAAD.2005.06.011
Botulinum toxin type A injections: adverse events reported to the US Food and Drug Administration in therapeutic and cosmetic cases.
T. Coté (2005)
10.1097/PHM.0b013e31806dbc3c
Kinematic Aiming Task: Measuring Functional Changes in Hand and Arm Movements After Botulinum Toxin-A Injections in Children with Spastic Hemiplegia
E. Rameckers (2007)
10.7326/0003-4819-141-10-200411160-00009
Better Reporting of Harms in Randomized Trials: An Extension of the CONSORT Statement
J. Ioannidis (2004)
10.3349/ymj.2006.47.5.589
Botulinum Toxin Type A Injection for Management of Upper Limb Spasticity in Children with Cerebral Palsy: a Literature Review
E. S. Park (2006)
10.1111/j.1468-1331.2006.01652.x
Safety and efficacy of botulinum toxin type A following long‐term use
M. Naumann (2006)
Inmunogical aspects of Botox
D Dressler (2006)
10.1017/S0012162201002547
Double-blind comparison study of two doses of botulinum toxin A injected into calf muscles in children with hemiplegic cerebral palsy
F. Polak (2002)
10.1097/01241398-200001000-00022
Botulinum Toxin Type A Neuromuscular Blockade in the Treatment of Lower Extremity Spasticity in Cerebral Palsy: A Randomized, Double-blind, Placebo-controlled Trial
L. Koman (2000)
10.2106/JBJS.F.01416
Does botulinum toxin a combined with bracing prevent hip displacement in children with cerebral palsy and "hips at risk"? A randomized, controlled trial.
H. Graham (2008)
10.1136/ADC.83.6.481
Randomised double blind placebo controlled trial of the effect of botulinum toxin on walking in cerebral palsy.
T. Ubhi (2000)
10.1191/0269215505cr859oa
The effect of botulinum toxin type A treatment of the lower extremity on the level of functional abilities in children with cerebral palsy: evaluation with goal attainment scaling
D. Steenbeek (2005)
Inmunogical aspects of Botox  , Dysport  and Myobloc TM / Neurobloc
D Dressler (2006)
10.1177/0269215509339882
Letter to the editor
A. J. Idrovo (2009)
10.2298/VSP0708513D
[Botulinum toxin type A for the treatment of spasticity in children with cerebral palsy].
L. Dimitrijević (2007)
10.1046/j.1440-1754.1999.00330.x
Botulinum toxin A versus fixed cast stretching for dynamic calf tightness in cerebral palsy
P. Flett (1999)
10.1111/j.1469-8749.2007.00331.x
A randomized controlled trial comparing botulinum toxin A dosage in the upper extremity of children with spasticity
Anne Kawamura (2007)
10.1016/S0966-6362(99)00012-0
Double-blind study of botulinum A toxin injections into the gastrocnemius muscle in patients with cerebral palsy.
D. Sutherland (1999)
10.1016/J.APMR.2006.08.342
The combined effect of lower-limb multilevel botulinum toxin type a and comprehensive rehabilitation on mobility in children with cerebral palsy: a randomized clinical trial.
V. Scholtes (2006)
10.1002/mds.1282
Botulinum toxin and short‐term electrical stimulation in the treatment of equinus in cerebral palsy
C. Detrembleur (2002)
10.1080/09638280701568296
Pharmacology of therapeutic botulinum toxin preparations
D. Dressler (2007)
10.1520/JFS2004196
Fatal case of BOTOX-related anaphylaxis?
M. Li (2005)
10.1002/SIM.1761
What to add to nothing? Use and avoidance of continuity corrections in meta-analysis of sparse data.
M. Sweeting (2004)
10.1111/j.1469-8749.2002.tb00268.x
Botulinum toxin treatment of spasticity in diplegic cerebral palsy: a randomized, double‐blind, placebo‐controlled, dose‐ranging study
R. Baker (2002)
10.1046/j.1468-1331.2001.00038.x
The effect of botulinum toxin type A on the functional ability of the child with spastic hemiplegia a randomized controlled trial
S. Love (2001)
10.1007/s00415-004-1102-z
Neurobiological basis for the use of botulinum toxin in pain therapy
S. Mense (2004)
10.1542/peds.2007-0016
Botulinum Toxin for Spasticity in Children With Cerebral Palsy: A Comprehensive Evaluation
K. Bjornson (2007)
10.2106/00004623-200411000-00003
Botulinum toxin as an adjunct to serial casting treatment in children with cerebral palsy.
R. Kay (2004)
10.1111/j.1469-8749.2007.00823.x
Repeat injection of botulinum toxin A is safe and effective for upper limb movement and function in children with cerebral palsy
K. Lowe (2007)
Functional outcomes of intramuscular cerebral palsy: a randomized controlled trial
M Wallen (2007)
10.1017/S0012162206001125
AACPDM systematic review of the effectiveness of therapy for children with cerebral palsy after botulinum toxin A injections.
N. Lannin (2006)
10.1017/S0012162206000041
Treatment of adductor spasticity with BTX‐A in children with CP: a randomized, double‐blind, placebo‐controlled study
V. Mall (2006)
10.1111/j.1468-1331.2006.01439.x
Immunological aspects of Botox®, Dysport® and MyoblocTM/NeuroBloc®
D. Dressler (2006)
10.1046/j.1468-1331.2001.00034.x
Current evidence for the use of botulinum toxin type A in the management of children with cerebral palsy: a systematic review
R. Boyd (2001)
Safety of botulinum toxin type A among children with spasticity secondary to cerebral palsy : a systematic review of randomized clinical trials
C Albavera-Hernández (2009)
Treatment of adductor spasticity with botulinum toxin type A in children with cerebral palsy: a randomized, double-blind, placebo-controlled study
V Mall (2006)
10.7205/MILMED.171.7.653
Comparison of the efficacies of botulinum toxin A and Johnstone pressure splints against hip adductor spasticity among patients with cerebral palsy: a randomized trial.
Bulent Hazneci (2006)
10.1185/030079904125003962
Safety of botulinum toxin type A: a systematic review and meta-analysis
M. Naumann (2004)
10.1017/S0012162206000387
Low‐dose/high‐concentration localized botulinum toxin A improves upper limb movement and function in children with hemiplegic cerebral palsy
K. Lowe (2006)
10.1111/J.1747-9991.2007.00106.X
Evidence in Medicine and Evidence‐Based Medicine
J. Worrall (2007)
10.1111/j.1469-8749.1997.tb07408.x
Botulinum toxin A in the hemiplegia upper limb: a double‐blind trial
I. S. Corry (1997)
10.33588/rn.3803.2003334
Evolución y tratamiento de la encefalopatía subaguda progresiva por virus de inmunodeficiencia humana en el niño: utilidad de la toxina botulínica
Antoni Noguera-Julian (2004)
Safety of botulinum toxin type A among children with spasticity secondary to cerebral palsy: a systematic review of randomized clinical trials
C Albavera-Hernández (2009)
10.1017/S0012162203001403
Botulinum toxin with and without casting in ambulant children with spastic diplegia: a clinical and functional assessment.
M. Bottos (2003)
10.1086/288768
Health as a Theoretical Concept
Christopher Boorse (1977)
10.1097/00001577-199801020-00013
Botulinum Toxin A in the Hemiplegic Upper Limb: A Double‐blind Trial
L. Arens (1997)
10.1046/j.1468-1331.2001.00043.x
The effect of botulinum toxin type A and a variable hip abduction orthosis on gross motor function: a randomized controlled trial
R. Boyd (2001)



This paper is referenced by
10.1136/practneurol-2011-000155
Spasticity: pathophysiology, evaluation and management
A. Kheder (2012)
10.1177/0269215510371430
Letter to the editor: Re: Safety of botulinum toxin type A among children with spasticity secondary to cerebral palsy: a systematic review of randomized clinical trials
Richard M. Dubinsky (2010)
10.1016/J.RBO.2013.08.005
Tratamento focal da espasticidade com toxina botulínica A na paralisia cerebral GMFCS nível V – Avaliação de efeitos adversos
A. P. Tedesco (2014)
10.1155/2012/678963
Medical Applications of Clostridia and Clostridial Toxins
M. Hale (2012)
10.1016/j.ejpn.2016.04.008
Safety profile of incobotulinum toxin A [Xeomin(®)] in gastrocnemious muscles injections in children with cerebral palsy: Randomized double-blind clinical trial.
E. Carraro (2016)
Chapter 2 Botulinum Toxin Adverse Events
R. Pero (2019)
10.1016/j.jbiomech.2013.07.028
Do skeletal muscle properties recover following repeat onabotulinum toxin A injections?
R. Fortuna (2013)
10.1016/j.jbiomech.2015.05.018
A clinically relevant BTX-A injection protocol leads to persistent weakness, contractile material loss, and an altered mRNA expression phenotype in rabbit quadriceps muscles.
R. Fortuna (2015)
10.1007/978-2-8178-0334-0_10
Traitement du déséquilibre musculaire du plexus brachial
Niria Quintero (2012)
10.1177/0883073814533196
Rationale for Using Botulinum Toxin A as an Adjunct to Upper Limb Rehabilitation in Children With Cerebral Palsy
B. Hoare (2014)
The relief effect of botulinum toxin-A for spastic iliopsoas of cerebral palsy on children.
J-J. Liu (2014)
10.1016/B978-1-4377-2369-4.00011-1
Chapter 11 – Stiffness syndromes
S. Fahn (2011)
10.1136/bmj.i157
PRISMA harms checklist: improving harms reporting in systematic reviews
L. Zorzela (2016)
10.1016/j.rboe.2014.04.022
Focal treatment of spasticity using botulinum toxin A in cerebral palsy cases of GMFCS level V: evaluation of adverse effects☆☆☆
A. P. Tedesco (2014)
10.1111/j.1468-1331.2010.03042.x
EFNS guidelines on diagnosis and treatment of primary dystonias
Alberto Albanese (2011)
10.1111/dmcn.12246
A systematic review of interventions for children with cerebral palsy: state of the evidence
I. Novak (2013)
10.1177/0883073813495306
Botulinum Toxin Type A in Children and Adolescents With Severe Cerebral Palsy
R. Mesterman (2014)
10.1016/j.ajem.2013.10.017
A new facial expression to botox!
A. Aggarwal (2014)
10.3390/toxins5030524
Safety of Botulinum Toxin A in Children and Adolescents with Cerebral Palsy in a Pragmatic Setting
A. Papavasiliou (2013)
10.7599/HMR.2016.36.1.59
Cerebral Palsy Update - Focusing on the Treatments and Interventions
M. Kim (2016)
10.1111/dmcn.13686
Severity of cerebral palsy and likelihood of adverse events after botulinum toxin A injections
Caitlyn M Swinney (2018)
10.1002/14651858.MR000030.pub2
Consolidated standards of reporting trials (CONSORT) and the completeness of reporting of randomised controlled trials (RCTs) published in medical journals.
Lucy Turner (2012)
10.1097/PHM.0b013e31829231fa
Use of Rimabotulinum Toxin for Focal Hypertonicity Management in Children with Cerebral Palsy with Nonresponse to Onabotulinum Toxin
J. Brandenburg (2013)
10.1016/j.pedhc.2020.04.010
Pharmacological Management of Spasticity in Children With Cerebral Palsy.
M. Reilly (2020)
10.1016/J.RH.2011.02.004
Valoración de la exactitud de la infiltración de toxina botulínica a ciegas en niños y adolescentes con parálisis cerebral
M. R. Pinero-Duran (2011)
10.1007/978-1-4614-5836-4_169
Botulinum neurotoxins as therapeutics
R. Mehanna (2014)
10.1016/j.jpeds.2014.01.050
Botulinum toxin A for nonambulatory children with cerebral palsy: a double blind randomized controlled trial.
L. Copeland (2014)
10.5772/66693
How Does Botulinum Toxin Injection and Physiotherapy Complement Each Other in Cerebral Palsy
A. Akbaş (2016)
10.1007/978-3-319-56038-0_6
Botulinum Toxin for Treatment of Spasticity in Cerebral Palsy
Kat Kolaski (2018)
10.1016/j.ejpn.2009.09.005
The updated European Consensus 2009 on the use of Botulinum toxin for children with cerebral palsy.
F. Heinen (2010)
10.1080/17518423.2018.1502832
Effects of Botulinum Toxin A Injection on Ambulation Capacity in Patients with Cerebral Palsy
S. Çağlar Okur (2019)
10.1017/S0317167100014049
Botulinum toxin-A use in paediatric hypertonia: Canadian practice patterns.
D. Fehlings (2012)
See more
Semantic Scholar Logo Some data provided by SemanticScholar